Provided by Tiger Trade Technology Pte. Ltd.

Nuvectis Pharma, Inc.

21.17
+1.045.17%
Volume:73.58K
Turnover:1.52M
Market Cap:689.75M
PE:-16.23
High:21.22
Open:20.11
Low:19.88
Close:20.13
52wk High:29.28
52wk Low:5.55
Shares:32.58M
Float Shares:21.23M
Volume Ratio:0.45
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3045
EPS(LYR):-1.3236
ROE:-214.58%
ROA:-73.07%
PB:75.95
PE(LYR):-15.99

Loading ...

Nuvectis Pharma to Participate in Maxim Growth Summit 2026 Panel Discussion

Reuters
·
Yesterday

Nuvectis Oncology Reaffirmed at Buy as Analyst Cites Differentiated BRAF Pipeline and Maintains $30 Price Target

TIPRANKS
·
Sep 25

Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset

TIPRANKS
·
Sep 25

Nuvectis Pharma Price Target Maintained with a $39.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 24

Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation in China for High-Grade Glioma

MT Newswires Live
·
Sep 24

Nuvectis Announces Nxp200 Granted Breakthrough Therapy Designation in China for Braf V600-Mutant, Recurrent or Progressive, High-Grade Glioma

THOMSON REUTERS
·
Sep 24

Nuvectis Pharma to Present at H.C. Wainwright Annual Investment Conference

Reuters
·
Sep 03

Nuvectis Pharma To Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 03

Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Aug 24

Nuvectis Pharma Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Aug 24

Nuvectis Pharma Launches New $200 Million ATM Program

TIPRANKS
·
Aug 22

Nuvectis Pharma files $200M mixed securities shelf

TIPRANKS
·
Aug 22

Nuvectis Pharma Sets up $200 Million At-the-Market Equity Program with Jefferies

Reuters
·
Aug 22

Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next

TIPRANKS
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Aug 06

Nuvectis Pharma: Buy Rating Reiterated as Late-Stage Pipeline Expands and $39 Price Target Remains Unchanged

TIPRANKS
·
Aug 05

Nuvectis Pharma Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Nuvectis Pharma Q2 FY26 Net Loss Widens to USD 7.02 Million

Reuters
·
Aug 04

Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate

Benzinga Earnings
·
Aug 04

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

THOMSON REUTERS
·
Aug 04